Literature DB >> 31186889

Novel local therapies in hepatocellular carcinoma.

Eleni Liapi1, Jean-Francois H Geschwind2.   

Abstract

Entities:  

Year:  2013        PMID: 31186889      PMCID: PMC6499304          DOI: 10.1002/cld.131

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN: 2046-2484


× No keyword cloud information.
  8 in total

Review 1.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

2.  Immunotherapy: Seek and destroy: oncolytic virus shows promise in phase I trial.

Authors:  Christoph A Schmitt
Journal:  Nat Rev Clin Oncol       Date:  2011-09-20       Impact factor: 66.675

3.  Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Authors:  Caroline J Breitbach; James Burke; Derek Jonker; Joe Stephenson; Andrew R Haas; Laura Q M Chow; Jorge Nieva; Tae-Ho Hwang; Anne Moon; Richard Patt; Adina Pelusio; Fabrice Le Boeuf; Joe Burns; Laura Evgin; Naomi De Silva; Sara Cvancic; Terri Robertson; Ji-Eun Je; Yeon-Sook Lee; Kelley Parato; Jean-Simon Diallo; Aaron Fenster; Manijeh Daneshmand; John C Bell; David H Kirn
Journal:  Nature       Date:  2011-08-31       Impact factor: 49.962

4.  Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.

Authors:  Eleni Liapi; Jean-Francois H Geschwind; Mustafa Vali; Afsheen A Khwaja; Veronica Prieto-Ventura; Manon Buijs; Josephina A Vossen; Shanmugasudaram Ganapathy-Kanniappan; Shanmugasudaram Ganapathy; Richard L Wahl
Journal:  J Nucl Med       Date:  2011-01-13       Impact factor: 10.057

5.  Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Authors:  Timothy M Pawlik; Diane K Reyes; David Cosgrove; Ihab R Kamel; Nikhil Bhagat; Jean-Francois H Geschwind
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

6.  Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Michael S Torbenson; Pramod P Rao; Kathryn A Carson; Manon Buijs; Mustafa Vali; Jean-François H Geschwind
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

7.  The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma.

Authors:  Ta-Chiang Liu; Taeho Hwang; Byeong-Ho Park; John Bell; David H Kirn
Journal:  Mol Ther       Date:  2008-07-15       Impact factor: 11.454

8.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

Authors:  Byeong-Ho Park; Taeho Hwang; Ta-Chiang Liu; Daniel Y Sze; Jae-Seok Kim; Hyuk-Chan Kwon; Sung Yong Oh; Sang-Young Han; Jin-Han Yoon; Sook-Hee Hong; Anne Moon; Kelly Speth; Chohee Park; Young-Joo Ahn; Manijeh Daneshmand; Byung Geon Rhee; Herbert M Pinedo; John C Bell; David H Kirn
Journal:  Lancet Oncol       Date:  2008-05-19       Impact factor: 41.316

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.